Newron Sweden AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Subsidiary
- Established
- 1998-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.neuronova.com
Study on Tolerability of Repeat i.c.v. Administration of sNN0031 Infusion Solution in Patients With PD
Phase 1
Terminated
- Conditions
- Parkinson's Disease
- Interventions
- Other: i.c.v. infusion of aCSF by an Implanted infusion systemOther: i.c.v. infusion of sNN0031 by an Implanted infusion system
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 1
- Registration Number
- NCT02408562
- Locations
- 🇩🇪
Klinikum-Bremerhaven, Bremerhaven, Germany
🇸🇪Lund University Hospital, Lund, Sweden
🇸🇪Karolinska University Hospital Huddinge, Stockholm, Sweden
A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS
Phase 1
Terminated
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: sNN0029 infusion solution
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 11
- Registration Number
- NCT02269436
- Locations
- 🇳🇱
Leonard van den Berg, Utrecht, Netherlands
🇧🇪Philip Van Damme, Leuven, Belgium
A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 15
- Registration Number
- NCT01999803
- Locations
- 🇧🇪
Philip Van Damme, Leuven, Belgium
🇳🇱Leonard van den Berg, Utrecht, Netherlands
A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 5
- Registration Number
- NCT01829867
- Locations
- 🇸🇪
Karolinska University Hospital Huddinge, Stockholm, Sweden
🇸🇪Skåne University Hospital Lund, Lund, Sweden
A Follow-up Study on Safety and Tolerability of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease
Completed
- Conditions
- Parkinson's Disease
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 11
- Registration Number
- NCT01807338
- Locations
- 🇸🇪
Department of Neurology, Skåne University Hospital, Lund, Sweden
An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 15
- Registration Number
- NCT01384162
- Locations
- 🇧🇪
University Hospital Leuven, Department of Neurology, Leuven, Belgium
A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2015-01-12
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 12
- Registration Number
- NCT00866502
- Locations
- 🇸🇪
Lund University Hospital, Lund, Sweden
🇸🇪Karolinska University Hospital, Huddinge, Stockholm, Sweden
A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2011-12-06
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 18
- Registration Number
- NCT00800501
- Locations
- 🇧🇪
University Hospital Leuven, Department of Neurology, Leuven, Belgium
© Copyright 2025. All Rights Reserved by MedPath